| INTRODUCTION
Left ventricular ejection fraction (LVEF) correlates with cardiovascular outcomes in heart failure (HF; Solomon et al., 2005) . For those with new-onset idiopathic nonischemic cardiomyopathy (NICM) and LVEF ≤35%, LVEF reassessment at 3 months has important therapeutic considerations. The 2013 American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) guideline for the management of HF recommends implantable cardioverter defibrillator (ICD) consideration for primary prevention of sudden death after a minimum of 3 months on guideline-directed medical therapy (GDMT) if the LVEF remains ≤35% (Yancy et al., 2013) . The AHA Science Advisory has also issued a class IIb recommendation for a wearable cardioverter defibrillator (WCD) in the setting of newly diagnosed NICM during the waiting period, but cautions against "blanket use" (Piccini et al., 2016) .
Prior studies suggest that approximately half of all subjects with new-onset idiopathic NICM and narrow QRS complex improve LVEF on GDMT such that they no longer meet criteria for ICD consideration (Teeter et al., 2012; Wang et al., 2016) . Predictors and implications of LVEF improvement 3 months after initial diagnosis of NICM with narrow QRS complex are not well described. The pertinent current literature is limited by lack of a standardized time of diagnosis to study entry period, lack of standardized time to LVEF reassessment, and/or high GDMT use at study entry (Binkley et al., 2008; Cicoira et al., 2001; Kadish et al., 2006; Kawai, et al., 1999; McNamara et al., 2011; Schliamser et al., 2013; Teeter et al., 2012; Zecchin et al., 2012) .
The NEw-Onset Left Bundle Branch Block-Associated Idiopathic
Nonischemic CardiomyopaTHy (NEOLITH) study assessed LVEF response to approximately 3 months of GDMT in newly diagnosed idiopathic NICM, LVEF ≤35%, and left bundle branch block or narrow QRS complex (Wang et al., 2016) . This substudy, comprises the narrow QRS complex control subjects, sought to address three main hypotheses:
(1) baseline characteristics predict early LVEF improvement, (2) early LVEF improvement predicts long-term clinical outcomes, and (3) some without early LVEF improvement will demonstrate LVEF improvement when followed for a longer time period.
| METHODS

| Study population and design
The NEOLITH study was a retrospective cohort study conducted at the University of Pittsburgh Medical Center (Wang et al., 2016) .
The 70 subjects in this study were those originally selected as narrow QRS complex controls. Subjects were prospectively identified based on a list used for clinical purposes to track those prescribed WCDs (ZOLL Medical Corporation, Pittsburgh, PA, USA) between January 2005 and April 2015. Subjects were prescribed WCDs for primary prevention during the GDMT waiting period. The derivation of the study cohort, the definition of new-onset idiopathic NICM, and exclusion criteria have been previously reported (Wang et al., 2016) . None were evaluated for myocarditis with viral serology or endomyocardial biopsy. The 12-lead electrocardiogram recorded at 25 mm/s at the time of the initial diagnosis of NICM was used to determine QRS duration. Automated measurements were confirmed by board-certified cardiologists. A QRS duration of <120 ms was classified as "narrow."
The date of the first imaging modality to reveal a LVEF ≤35% was designated the date of diagnosis. GDMT was administered at the discretion of treating cardiologists. For new-onset NICM, our electrophysiology group generally recommends a transthoracic echocardiogram to assess LVEF approximately 3 months after initiation of GDMT. Subjects with persistent LVEF ≤35% are considered for ICDs in accordance with ACCF/AHA guideline recommendations (Yancy et al., 2013) . ICD implants were performed using a transvenous approach by electrophysiologists at the University of Pittsburgh Medical Center. Device programming was at the discretion of the implanting physicians. This study was approved by the University of Pittsburgh Institutional Review Board. Informed consent was not required due to the retrospective design.
| Exposures and outcomes
Body mass index, heart rate, systolic blood pressure, serum sodium level, serum blood urea nitrogen level, and serum creatinine level were those measured on admission during the index hospitalization or closest to the index outpatient clinic appointment when WCDs were prescribed. Alcohol consumption was defined as none, light, moderate, heavy, binge, and prior heavy and/or binge drinking based on a previously recommended scale (Kloner & Rezkalla, 2007) . For the analyses, light and moderate drinking were combined and heavy and binge drinking were combined. Angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II receptor blocker (ARB) were collapsed into one variable. Percent target doses achieved for ACEIs/ARBs, β-blockers, and aldosterone antagonists were calculated as previously described (Wang et al., 2016) . Antiarrhythmic medications were all Vaughan-Williams class III.
Left ventricular ejection fraction was determined by objective imaging techniques and confirmed by board-certified cardiologists.
Transthoracic echocardiography was the most common modality and therefore used when available for consistency. LVEF was determined by visual estimation to confirm objective measurements, such as biplane Simpson's method and Teichholz's formula (Lang et al., 2015) . When reported as a range, the midpoint was assigned (i.e., 32.5% for LVEF reported as 30%-35%). LVEF measurements were those originally reported and used to make clinical decisions.
Left ventricular end-diastolic diameter (LVEDD) was assessed on transthoracic echocardiography in the parasternal long-axis view.
LVEDD was assessed as both categorical and continuous variables.
LVEDD as a categorical variable was sex based as recommended by the American Society of Echocardiography and classified as normal (men, 4.2-5.8 cm; women, 3.8-5.2 cm), mildly dilated (men, 5.9-6.3 cm; women, 5.3-5.6 cm), moderately dilated (men, 6.4-6.8 cm; women, 5.7-6.1 cm), and severely dilated (men, ≥6.9 cm; women, ≥6.2 cm; Lang et al., 2015) . We also analyzed LVEDD as a continuous variable without accounting for sex given similar supplementary analyses in other publications (McNamara et al., 2011) .
The primary short-term outcome measure of LVEF approximately 3 months after starting GDMT was designated the "post-GDMT LVEF." A categorical outcome was dichotomized as post-GDMT LVEF ≤35% vs. >35%. This threshold for LVEF improvement was selected based on guideline recommendations for primary prophylaxis ICDs (Yancy et al., 2013) . A continuous outcome was defined as the absolute difference between post-GDMT LVEF and initial LVEF, or
The primary long-term outcome measure was a composite of adverse cardiac events including HF rehospitalization, appropriate WCD shock, resuscitated out-of-hospital cardiac arrest, appropriate anti-tachycardia pacing (ATP) therapy, appropriate ICD shock, ventricular assist device implantation, heart transplantation, and death. If appropriate ATP therapy and ICD shock occurred during the same event, only ICD shock was counted. The inception point of this time period was the date of initial NICM diagnosis.
Long-term events were assessed by review of medical records on June 6, 2016. The "long-term LVEF" was the most recent available given the lack of a standardized time period for subsequent measurements.
| Statistical methods
Descriptive data were presented by post-GDMT LVEF ≤35% and >35%. Categorical variables were compared using chi-square or Fisher's exact tests as appropriate. Continuous variables were compared using Student's t test or Wilcoxon-Mann-Whitney test as appropriate.
Logistic regression models were used to assess associations between baseline characteristics and postdiagnosis medications with post-GDMT LVEF ≤35% and >35%. Linear regression models were used to assess associations between baseline characteristics and postdiagnosis medications with ΔLVEF GDMT . Time-to-event outcomes between post-GDMT LVEF groups were summarized using Kaplan-Meier survival curves, and differences between groups were summarized by the hazard ratio (HR) and 95% confidence interval (CI) computed using the Cox proportional hazards model. For multivariable analyses, variables that were found to be significantly associated with the outcomes at p < .1 were considered. Age, sex, and race/ ethnicity were forced into the models. ACEIs/ARBs and β-blockers were also forced into the models given prior publications describing associations with LVEF improvement (Konstam et al., 1992; Packer et al., 2001) . Sensitivity analysis was performed on subjects who received both ACEIs/ARBs and β-blockers. We did not assign a value for "significance" for reported p-values given the recent statement by the American Statistical Association, but recognize the traditional threshold of p < .05 (Wasserstein & Lazar, 2016) . All analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC, USA).
| RESULTS
The baseline characteristics of the total cohort and by post-GDMT LVEF status are presented in Table 1 ; 39 (56%) subjects demonstrated LVEF improvement to >35%. The presenting rhythm was sinus in 69 subjects and atrial fibrillation in one subject. Tachycardiainduced cardiomyopathy was not felt to be of high consideration in the subject who presented with atrial fibrillation. Of the 70 subjects, 69 were diagnosed in an inpatient hospitalized setting and had a length of stay of 6.5 ± 5.4 days. The length of stay was similar in groups that did and did not have post-GDMT LVEF improvement (6.4 ± 4.7 days vs. 6.5 ± 6.3 days; p = .73). Imaging modalities used to assess initial LVEF included transthoracic echocardiography (n = 64), single photon emission computed tomography (n = 2), and ventriculography (n = 4).
Prediagnosis and postdiagnosis cardiovascular medications are listed in Table 2 . Those with LVEF improvement received higher doses of β-blockers. ACEIs/ARBs used included lisinopril (n = 45), enalapril (n = 6), ramipril (n = 4), captopril (n = 2), quinapril (n = 2) valsartan (n = 4), and losartan (n = 3). β-blockers used included carvedilol (n = 60), metoprolol succinate (n = 6), metoprolol tartrate (n = 1), and atenolol (n = 1). Four were not on either ACEI or ARB due to renal dysfunction (n = 2), low blood pressure (n = 1), and a reason that was not specified (n = 1). Two subjects were not on β-blockers, one for noncompliance and the other for low blood pressure.
The median follow-up time to post-GDMT LVEF measurement was 97.5 days (interquartile range (IQR), 84-121 days) and similar between post-GDMT LVEF ≤35% and >35% groups (91 days; IQR, 85-110 days vs. 103 days; IQR, 78-144 days; p = .62). Imaging modalities used to assess post-GDMT LVEF included transthoracic echocardiography (n = 63), multigated acquisition scan (n = 4), and cardiovascular magnetic resonance imaging (CMR) (n = 3). The mean post-GDMT LVEF was 23.3% ± 5.9% in the ≤35% group and 49.1% ± 8.4% in the >35% group (p < .0001). Among those with LVEF improvement, 18 subjects had LVEF ≥50%. In the post-GDMT LVEF >35% group, 33 (84.6%) subjects had ∆LVEF GDMT ≥15% compared with 3 (9.7%) subjects in the post-GDMT LVEF ≤35% group (p < .0001). The mean ∆LVEF GDMT was 16.1% ± 14.6% for the entire cohort. The mean ∆LVEF GDMT was 26.0% ± 10.8% in the post-GDMT LVEF >35% group and 3.7% ± 7.3% in the post-GDMT ≤35% group (p < .0001).
The median WCD use time was 94.8 days (IQR, 40-111 days) and 20.6 hr/day (IQR, 15.9-23.2 hr/day). There were no appropriate WCD shocks.
The 31 subjects with post-GDMT LVEF ≤35% underwent the following procedures: 20 had single-chamber ICDs, six had dual-chamber ICDs, one had a CRT-D, three were recommended ICDs but declined, and one met criteria for an ICD but sought treatment elsewhere. One subject with a QRS duration of 80 ms received a CRT-D device in the year 2006 on the basis of echocardiographic mechanical dyssynchrony.
In the 39 subjects with post-GDMT LVEF >35%, two subjects received dual-chamber ICDs. No others received cardiovascular implantable electronic devices. One subject was implanted 9 days after initial diagnosis of NICM due to sinus pauses of >7 s in the absence of Hyperlipidemia, n (%) 8 (11) 2 (6) 6 (15) .29
Chronic obstructive pulmonary disease, n (%) 7 (10) 3 (10) 4 (10) 1.0
Obstructive sleep apnea, n (%) 3 (4) 2 (6) 1 (3) .58
Depression, n (%) 8 (11) 4 (13) 4 (10) 1.0 Former heave or binge 5 (7) 2 (6) 3 (8) GDMT, guideline-directed medical therapy; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; SD, standard deviation; yr, year. a Post-GDMT LVEF ≤35% group versus post-GDMT LVEF >35% group. discernible causes; her post-GDMT LVEF was 57.5%. Another was implanted for a post-GDMT LVEF of 37.5% and died of unknown causes 7 months after ICD placement.
| Associations of baseline characteristics and postdiagnosis medications with early LVEF improvement
In univariable logistic regression analyses, mildly and severely dilated initial LVEDD, when compared to normal initial LVEDD, were associated with lower odds of post-GDMT LVEF >35% (Table 3) . This association was also present for the continuous initial LVEDD variable. These relationships were maintained in multivariable analyses (Table 4) . Inverse adjusted odds ratios (ORs) modeled for the lack of LVEF improvement, or post-GDMT ≤35%, were 7.01 (95% CI, 1.17- 
| Long-term adverse cardiac events
The median long-term follow-up period was 970.5 days (IQR, 321-1639 days). Adverse cardiac events were more common in the post-GDMT LVEF ≤35% group (Table 5 and Figure 2 ). 
| Long-term LVEF in the post-GDMT LVEF ≤35% group
In 31 subjects with post-GDMT LVEF ≤35%, 26 had long-term LVEF assessments after a median follow-up time (measured from post-GDMT LVEF measurements) of 1051.5 days (IQR, 811-1,639; Table 6 ). There were nine (35%) subjects with long-term LVEF >35%, but two within this group had appropriate ICD therapies. One was a 37-year-old man with late gadolinium enhancement (LGE) on CMR suggestive of midwall myocardial fibrosis and nonsustained ventricular tachycardia (NSVT) up to 14 beats.
| DISCUSSION
This analysis of subjects with new-onset idiopathic NICM with narrow QRS complex from the NEOLITH study was unique due to complete absence of ACEI/ARB and β-blocker use for HF indications at the time of initial diagnosis and a standardized 3-month follow-up LVEF measurement after GDMT initiation. We noted several important observations. First, there were strong associations between mildly and severely dilated initial LVEDD and lack of early LVEF improvement, when compared with normal initial LVEDD. Second, lack of early LVEF improvement identified a population at potentially higher risk for long-term adverse cardiac events. Third, over one-third with LVEF ≤35% after 3 months of GDMT had continued improvement to LVEF >35% during long-term follow-up.
The Intervention in Myocarditis and Acute Cardiomyopathy-2 study enrolled subjects with NICM and symptoms for <6 months (McNamara et al., 2011) . Subjects were already receiving GDMT at the time of enrollment as 91% were receiving ACEIs and/or ARBs and 82% were receiving β-blockers. ICDs were present in 7% at enrollment. LVEDD was the strongest predictor of LVEF improvement at 6 months. Despite study differences, our findings are complementary. The Genetic Risk Assessment of Defibrillator Events study evaluated subjects with LVEF ≤30% and ICDs (Aleong et al., 2015) . Greater LVEDD, even after adjusting for LVEF, was associated with a higher risk for both appropriate ICD shocks and time to death, transplant, or ventricular assist device. Although the majority of subjects had ischemic etiology, the association persisted when adjusted for etiology of cardiomyopathy. This supports the concept that greater LVEDD represents a higher risk subgroup with potentially different pathophysiologic underpinnings.
Those with new-onset NICM have very low rates of sustained ventricular arrhythmias in the early postdiagnosis period (Kutyifa et al., 2015; Singh et al., 2015) . No randomized controlled trials have demonstrated mortality reduction with WCD use in this population.
WCDs for all subjects with new-onset NICM and LVEF ≤35% are not recommended by the AHA Science Advisory, but specific recommendations for identifying higher risk individuals who may potentially benefit were not issued (Piccini et al., 2016) . It must also be recognized that the LVEF cutoffs are derived from randomized clinical trials for primary prevention ICDs with long-term follow-up times of several years. A 23% risk reduction in death was observed with ICDs in addition to GDMT in the Sudden Cardiac Death in Heart Failure Trial, but the median follow-up time was 3.8 years (Bardy et al., 2005) .
Our results suggest a larger LVEDD deserves further investigation as a potential high-risk marker for which WCDs may be considered. Although we did not observe any appropriate WCD shocks, our sample size was relatively small. Unexpectedly, mild and severe dilated LVEDD were associated with less LVEF improvement compared with normal LVEDD, but moderately dilated LVEDD was not. This may be a statistical anomaly related to low sample size given the large strength of association observed in the other analyses. The cutoff, if any, at which point WCD may confer benefit should be investigated.
In our study, subjects without LVEF improvement 3 months after initial diagnosis, when compared with those with improvement, were at higher risk for long-term adverse cardiac events. ICDs may be considered at that time, but whether there is a difference in outcomes between ICD placement at 3 months compared with a later time period is unknown. Death from worsening HF is the primary cause of death in those hospitalized for decompensated HF and chronically reduced LVEF (Wang et al., 2008) . The benefit of defibrillator therapy to decrease sudden death due to arrhythmias for many months postdischarge may, therefore, be nullified by the competing risk of HF death (Wang et al., 2010 ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CI, confidence interval; GDMT, guideline-directed medical therapy; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; OR, odds ratio; SE, standard error; ΔLVEF GDMT , post-GDMT LVEF − initial LVEF.
Some HF centers reserve ICD consideration based on LVEF assessment 6 months after reaching maximally tolerated doses of β-blockers (Teeter et al., 2012) . A trade-off exists between implanting too early in those who may further improve LVEF and implanting too late in those who may have ventricular arrhythmias while waiting. A small study comprised mostly NICM subjects demonstrated continuous improvement in remodeling over 18 months (Hall et al., 1995) . They observed LVEF measurements of 24% ± 8% at baseline, 33% ± 10% at 3 months, and 44% ± 13% at 18 months. It is theoretically possible for Over one-third of our subjects with LVEF ≤35% at 3 months demonstrated continued LVEF improvement with longer duration of treatment, suggesting that a longer time period than 3 months may be prudent prior to ICD consideration. Appropriate ICD therapies for ventricular arrhythmias, however, still occurred in this group over long-term follow-up. One subject had both NSVT and late gadolinium enhancement on CMR. In the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial, subjects with NICM of ≤3 months duration demonstrated a lower rate of death when ICDs were used in addition to GDMT, whereas the death rate was not lower in the ICD group when the NICM duration was >3 months (Kadish et al., 2006) . This may reflect referral bias of subjects with perceived higher sudden death risk being referred earlier for study enrollment.
Ventricular ectopy, defined as NSVT 3-15 beats at >120 bpm or >10 T A B L E 4 Multivariable logistic and linear regression analyses for associations between initial LVEDD and LVEF response to GDMT premature ventricular complexes per hour, was an inclusion criteria in this trial (Kadish et al., 2004) . This risk marker may be useful when considering WCD and/or earlier ICD recommendation.
Cardiovascular magnetic resonance imaging may play a future role in guiding optimal timing for ICD recommendation.
LGE detected on CMR has been shown to predict LVEF improvement on β-blocker treatment (Bello et al., 2003) . CMR has also been demonstrated to increase prediction for mortality and sudden death in subjects with NICM (Gulati et al., 2013) . Echocardiographic LVEDD measurement may be valuable to determine which subjects with new-onset NICM should be referred for CMR for further risk stratification. Theoretically, those without LGE may be allowed a longer time on GDMT given ATP, antitachycardia pacing; GDMT, guideline-directed medical therapy; HF, heart failure; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NA, not applicable; WCD, wearable cardioverter defibrillator.
a Post-GDMT LVEF ≤35% group versus post-GDMT LVEF >35% group. b For any event, only the first event per subject was counted.
T A B L E 5 Long-term adverse cardiac events based on post-GDMT LVEF status F I G U R E 2 Kaplan-Meier curve for probability of survival from adverse cardiac events based on post-GDMT LVEF status. In the post-GDMT LVEF ≤35% group, compared with the >35% group, the unadjusted hazard ratio for adverse cardiac events was 2.15 (95% confidence interval, 0.93-4.96; p = .07). GDMT, guideline-directed medical therapy; LVEF, left ventricular ejection fraction higher chance of LVEF improvement and lower risk for arrhythmic death. Conversely, those with significant areas of LGE may be strongly considered for ICD placement at 3 months, or even sooner, if the LVEF remains ≤ 35%.
| Study limitations
Our findings should be considered hypothesis generating and not conclusive given the retrospective design of our study. Our subjects were T A B L E 6 Characteristics of 31 subjects with post-GDMT LVEF ≤35%, listed by long-term LVEF Including appropriate ATP therapy and ICD shocks may have tilted the measure of adverse cardiac events against the post-GDMT group (Ellenbogen et al., 2006) . We did not have a core echocardiography laboratory to standardize measurements. There was no systematic screening for ventricular ectopy. The overall use of CMR was low.
| CONCLUSION
In our study of subjects with new-onset idiopathic NICM with narrow QRS complex, severely dilated LVEDD strongly predicted lack of LVEF improvement after approximately 3 months on GDMT. Subjects without LVEF improvement at 3 months are at higher risk for adverse car- 
